Long-term symptom recovery and health-related quality of life in patients with mild-to-moderate-severe community-acquired pneumonia

被引:73
作者
el Moussaoui, Rachida
Opmeer, Brent C.
de Borgie, Corianne A. J. M.
Nieuwkerk, Pythia
Bossuyt, Patrick M. M.
Speelman, Peter
Prins, Jan M.
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Med Psychol, NL-1105 AZ Amsterdam, Netherlands
关键词
community-acquired pneumonia; Medical Outcomes Study 36-item short form questionnaire; symptom resolution; validated patient-based outcome measures;
D O I
10.1378/chest.130.4.1165
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objectives: The long-term outcomes of patients with community-acquired pneumonia (CAP) in terms of symptom resolution and health-related quality of life (HRQL) is unknown. Our objective was to determine the rate of symptom resolution using validated patient-based outcome measures, and to assess HRQL IS months after the episode. Participants: Patients were recruited from a group enrolled in a randomized trial comparing two durations of treatment for CAP. Between 2000 and 2003, we included 102 adults with a mild-to-moderate-severe CAP (pneumonia severity index, <= 110). Interventions: CAP-related symptoms were assessed until month IS using the CAP score. The CAP score was divided into respiratory and well-being sections to assess the recovery of respiratory and well-being symptoms separately. The HRQL was assessed at IS months using the Medical Outcomes Study 36-item short form (SF-36) questionnaire and compared to a Dutch reference group. Results: Respiratory symptoms resolved within 14 days, while the well-being symptoms resolved more slowly. Taking the prepneumonia status into account, patients recovered fully from pneumonia after 6 months. Patients with comorbid conditions had significantly more symptoms prepneumonia and during follow-up than patients without comorbidities, but at all time points the proportion of patients that reached >= 80% of the prepneumonia health level did not depend on comorbidity, age, or etiology. SF-36 scores at IS months were significantly impaired in four of the eight dimensions for patients with comorbid illness, but did not differ from the reference population for patients without comorbid illness. Conclusion: Patients with mild-to-moderate-severe CAP recover fully from pneumonia after 6 months. The presence of symptoms beyond 28 days and any impairment in HRQL were found to reflect age and comorbidity rather than the persistent effects of the pneumonia itself.
引用
收藏
页码:1165 / 1172
页数:8
相关论文
共 19 条
[1]   Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations [J].
Aaronson, NK ;
Muller, M ;
Cohen, PDA ;
Essink-Bot, ML ;
Fekkes, M ;
Sanderman, R ;
Sprangers, MAG ;
Velde, AT ;
Verrips, E .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (11) :1055-1068
[2]   Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians, and policy-makers [J].
Barlow, GD ;
Lamping, DL ;
Davey, PG ;
Nathwani, D .
LANCET INFECTIOUS DISEASES, 2003, 3 (08) :476-488
[3]   Regulating the use of antibiotics in the community [J].
Carbon, C ;
Bax, RP .
BRITISH MEDICAL JOURNAL, 1998, 317 (7159) :663-665
[4]  
Cohen J., 1988, STAT POWER ANAL BEHA
[5]   Development and validation of a short questionnaire in community acquired pneumonia [J].
El Moussaoui, R ;
Opmeer, BC ;
Bossuyt, PMM ;
Speelman, P ;
de Borgie, CAJM ;
Prins, JM .
THORAX, 2004, 59 (07) :591-595
[6]   Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study [J].
el Moussaoui, Rachida ;
de Borgie, Corianne A. J. M. ;
van den Broek, Peterhans ;
Hustinx, Willem N. ;
Bresser, Paul ;
van den Berk, Guido E. L. ;
Poley, Jan-Werner ;
van den Berg, Bob ;
Krouwels, Frans H. ;
Bonten, Marc J. M. ;
Weenink, Carla ;
Bossuyt, Patrick M. M. ;
Speelman, Peter ;
Opmeer, Brent C. ;
Prins, Jan M. .
BMJ-BRITISH MEDICAL JOURNAL, 2006, 332 (7554) :1355-1358
[7]   Processes and outcomes of care for patients with community-acquired pneumonia - Results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study [J].
Fine, MJ ;
Stone, RA ;
Singer, DE ;
Coley, CM ;
Marrie, TJ ;
Lave, JR ;
Hough, LJ ;
Obrosky, DS ;
Schulz, R ;
Ricci, EM ;
Rogers, JC ;
Kapoor, WN .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (09) :970-980
[8]   A prediction rule to identify low-risk patients with community-acquired pneumonia [J].
Fine, MJ ;
Auble, TE ;
Yealy, DM ;
Hanusa, BH ;
Weissfeld, LA ;
Singer, DE ;
Coley, CM ;
Marrie, TJ ;
Kapoor, WN .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (04) :243-250
[9]   Causes and consequences of comorbidity: A review [J].
Gijsen, R ;
Hoeymans, N ;
Schellevis, FG ;
Ruwaard, D ;
Satariano, WA ;
van den Bos, GAM .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2001, 54 (07) :661-674
[10]   Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia [J].
Gleason, PP ;
Kapoor, WN ;
Stone, RA ;
Lave, JR ;
Obrosky, DS ;
Schulz, R ;
Singer, DE ;
Coley, CM ;
Marrie, TJ ;
Fine, MJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (01) :32-39